JPRN-UMIN000032548已完成未知
The effect of rifaximin on liver cirrhosis patients with hepatic encephalopathy - The effect of rifaximin on liver cirrhosis patients with hepatic encephalopathy
ara Medical University0 个研究点目标入组 50 人开始时间: 2018年5月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria are cardiac and/or respiratory failure or invasive cancer within the past 5 years; renal failure; clinical or biochemical signs of infection 28 d prior to inclusion; concomitant inflammatory bowel diseases and/or irritable bowel syndrome; previous history of gastrectomy, enterectomy, and/or liver transplantation; and developed portosystemic shunt. Patients who consume nonabsorbable disaccharides, probiotics, prebiotics, synbiotics, or other antibiotics 28 days prior to inclusion are also excluded.
研究者
相似试验
已完成
不适用
Study on the effect of rifaximin on cirrhosisHepatic encephalopathy (Overt encephalopathy, Covert encephalopathy) HyperammonemiaJPRN-UMIN000044146Hokkaido University Hospital150
Unknown
3 期
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal VaricesLiver CirrhosisPortal HypertensionNCT02508623University of Padova60
招募中
不适用
Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot studyhepatic encephalopathyJPRN-UMIN000032308Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan30
招募中
不适用
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver CirrhosisDecompensated CirrhosisNCT05863364Xin Zeng150
撤回
4 期
Rifaximin Versus Lactulose in Renal FailureLiver CirrhosisRenal FailureNCT00748904Weill Medical College of Cornell University